The U.S. Patent and Trademark Office (USPTO) has issued to Impel NeuroPharma, Inc. a patent relating to the company’s Precision Olfactory Delivery™ or POD™ technology. Patent number 9,919,117, entitled “NOZZLES FOR NASAL DRUG DELIVERY,” is directed to nozzles used in the POD™ technology to allow drug administration into the deep...

Impel co-founder and CSO, Dr. John Hoekman, presented today at 11:00 AM on a panel discussing, "What’s New in Alzheimer’s and Other Neurodegenerative Diseases?" at Life Science Innovation Northwest 2018 in Seattle, WA. The panel was moderated by Dr. Adrian Hobden, President & CEO of CereSpir. Dr. John Hoekman was joined by Dr. Leen Kawas, President & CEO...

Impel's CEO, Jon Congleton, CSO, Dr. John Hoekman, and CMO, Dr. Stephen Shrewsbury, will be presenting at Cowen's 38th Annual Health Care Conference in Boston, MA on Wednesday, March 14th from 1:30 - 1:55 PM EDT. For more information, visit www.cowen.com/capabilities/conferences-events. ...

Novel, Intranasal Dihydroergotamine Dosed via Precision Olfactory Delivery, or POD™, Device Achieved Primary Outcome of Bioavailability, Safety Study Marks First of Four Impel Clinical Trial Read Outs Planned for 2018 SEATTLE, Feb. 7, 2018  -- Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today...